Actively Recruiting
Adaptive Phase 12 Study of VV-14305 Gene Therapy Injected Around the Eye for Moderate to Severe Thyroid Eye Disease
Led by Kriya Therapeutics, Inc. · Updated on 2026-08-27
135
Participants Needed
5
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of VV-14305 also called KRIYA-586 for treating thyroid eye disease TED, a condition that affects the eyes in people with thyroid disorders. This adaptive phase 12 trial aims to understand how this gene therapy delivered by peribulbar injection impacts moderate to severe TED. The study is sponsored by Kriya Therapeutics, Inc. and includes both early and later treatment phases. Participants receive a single dose of VV-14305 injected around the eye, combined with prednisone treatment before and after the injection. Several cohorts receive escalating doses, and a sham injection group is included for comparison. The study has two parts an initial dose-escalation phase and a second phase comparing the active treatment to a sham injection. Prednisone is given around the time of the injections in all groups. During the study, participants undergo regular assessments over a 52-week period to monitor safety, drug effects, and eye condition changes. Researchers evaluate measures such as safety, tolerability, efficacy at reducing TED symptoms, quality of life, and drug levels in the body. Participants are closely followed for one year after treatment to track outcomes and any side effects, with scheduled visits and evaluations throughout this time.
CONDITIONS
Brief Title
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
Research Team
V
VP, Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here